Drug

Proteasomal Ubiquitin Receptor ADRM1 clinical trials

studies test it: 16
open now: 4
in phase 3: 3
first study started: 2007

Keep track of what changes. Save the Proteasomal Ubiquitin Receptor ADRM1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Arm 1: 8
Arm1: 4

Studies by the year they started

16 studies that test it; most in 2024 (3)

Studies that test Proteasomal Ubiquitin Receptor ADRM1, by start year
Year	Studies
2007	2
2010	1
2011	1
2014	2
2015	1
2019	1
2023	2
2024	3
2025	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 4
Phase 2: 8
Phase 3: 3
Phase 4: 1
No phase: 1

What it is tested for

Each study’s main condition, where its own words name it.

Esophageal Neoplasms: 1
Coronary Disease: 1
Post-Acute COVID-19 Syndrome: 1
Polycystic Ovary Syndrome: 1
Colitis, Ulcerative: 1
Gout: 1
Macular Edema: 1
Head and Neck Neoplasms: 1
Colorectal Neoplasms: 1
Carcinoma, Non-Small-Cell Lung: 1
Leiomyoma: 1
Small Cell Lung Carcinoma: 1

Who runs them

Industry 6 · Other 10

Sun Yat-sen University (2) · University of Manitoba (1) · Indication Bioscience LLC (1) · Bateman Horne Center (1) · University of Chicago (1) · Zydus Lifesciences Limited (1) · JW Pharmaceutical (1) · Novartis Pharmaceuticals (1)

Often tested with

Tested in the same studies.

Fospropofol (1) · Propofol (1) · Acetaminophen (1) · Tunlametinib (1) · Fulzerasib (1) · Erlotinib (1)

Studies

Open first, then newest update. How each study uses Proteasomal Ubiquitin Receptor ADRM1 is read from its arms, and is right about nine times in ten.